Clinical question: Does inhaled amikacin reduce the incidence of ventilator-associated pneumonia (VAP) in critically ill patients? Background: VAP is a common and serious complication in patients on ...

In a report released on January 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Insmed (INSM – Research Report), with a ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $98.00.

ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ...

Vectura’s expertise in the field includes formulation and device development for dry powder inhalers and pressurized metered dose inhalers, among other products and services.

Background: A 2021 study reported neurologic... Clinical question: Does inhaled amikacin reduce the incidence of ventilator-associated pneumonia (VAP) in critically ill patients? Background: VAP is a ...

Insmed is a biopharmaceutical company that focuses on developing novel therapeutics for rare diseases. Its marketed product, Arikayce (liposomal amikacin for inhalation) is indicated for mycobacterium ...

Taiwan’s Air Force said the officer was "inhaled by the engine for unknown reasons." She later was pronounced dead after life-saving efforts were unsuccessful. "In response to media reports that ...